MedPath

Perioperative Risk Study

Not Applicable
Active, not recruiting
Conditions
Primary Neoplasm
Surgery
Tumors
Secondary Neoplasm
Interventions
Other: Standard postoperative care
Other: Preoperative risk stratification
Other: Postoperative risk stratification
Other: Risk-based, escalating levels of care
Other: Risk-based, escalating levels of monitoring
Other: Risk-based, escalating levels of co-management
Registration Number
NCT02456389
Lead Sponsor
Fox Chase Cancer Center
Brief Summary

The primary objective of this trial is to determine if perioperative risk stratification and risk-based, protocol-driven management leads to a reduction in the rate of death or serious complications compared to standard perioperative management in patients undergoing elective major cancer surgery.

Detailed Description

Major cancer surgery is associated with significant rates of postoperative mortality and major morbidity. Postoperative morbidity adversely impacts healthcare utilization, healthcare costs, rates of discharge to home, quality of life, rates of receipt of postoperative anti-neoplastic therapy, disease-free survival, and overall survival. The investigators hypothesize that perioperative risk stratification and risk-based, protocol-driven management (compared to standard perioperative management) will lead to a reduction in 30-day post-operative mortality or major morbidity in patients undergoing major cancer surgery. This is based on our theory that preoperative/postoperative use of newly developed, perioperative risk-prediction tools will help identify patients at increased risk of postoperative death or serious complications that might benefit from risk-based, protocol-driven perioperative management, including escalating levels of care, escalating levels of monitoring, and escalating levels of hospitalist co-management. The set of assessments and interventions in the proposed study are conceptually similar to other "bundled" interventions which have recently been recently tested and demonstrated to reduce perioperative mortality and morbidity.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
1456
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Standard perioperative managementStandard postoperative careStandard postoperative care
Risk-based, perioperative managementPreoperative risk stratificationPreoperative risk stratification Postoperative risk stratification Risk-based, escalating levels of care Risk-based, escalating levels of monitoring Risk-based, escalating levels of co-management
Risk-based, perioperative managementPostoperative risk stratificationPreoperative risk stratification Postoperative risk stratification Risk-based, escalating levels of care Risk-based, escalating levels of monitoring Risk-based, escalating levels of co-management
Risk-based, perioperative managementRisk-based, escalating levels of monitoringPreoperative risk stratification Postoperative risk stratification Risk-based, escalating levels of care Risk-based, escalating levels of monitoring Risk-based, escalating levels of co-management
Risk-based, perioperative managementRisk-based, escalating levels of carePreoperative risk stratification Postoperative risk stratification Risk-based, escalating levels of care Risk-based, escalating levels of monitoring Risk-based, escalating levels of co-management
Risk-based, perioperative managementRisk-based, escalating levels of co-managementPreoperative risk stratification Postoperative risk stratification Risk-based, escalating levels of care Risk-based, escalating levels of monitoring Risk-based, escalating levels of co-management
Primary Outcome Measures
NameTimeMethod
Rate of death or serious complications (as defined by American College of Surgeons National Surgical Quality Improvement Program [ACS NSQIP])30-day postoperative period
Secondary Outcome Measures
NameTimeMethod
Rate of return to the operating room30-day postoperative period
Rate of primary intensive care unit admissionFrom date of index surgery to date of hospital discharge, up to 3 months
Overall survivalFrom date of index surgery to date of death, loss to follow-up, or end of study, whichever comes first, assessed up to 60 months
Rate of death30-day postoperative period
Rate of Clavien-Dindo grade IIIa-V complication (as defined by ACS NSQIP)30-day postoperative period
Rate of Clavien-Dindo grade IIIa-V adverse event (as defined by CTCAE)30-day postoperative period
Rate of pulmonary complications30-day postoperative period
Rate of renal complications30-day postoperative period
Rate of infectious complications30-day postoperative period
Rate of secondary intensive care unit admissionFrom date of index surgery to date of hospital discharge, up to 3 months
Length of stayFrom date of index surgery to date of hospital discharge, up to 3 months
Rate of serious/grade 3-4 adverse event (as defined by CTCAE)30-day postoperative period
Rate of serious complication (as defined by ACS NSQIP)30-day postoperative period
Rate of cardiac complications30-day postoperative period
Rate of wound complications30-day postoperative period
Total hospital chargesFrom date of index surgery to date of hospital discharge, up to 3 months
Rate of discharge to homeFrom date of index surgery to date of hospital discharge, up to 3 months
Rate of hospital readmission30-day postoperative period
Receipt of anti-neoplastic therapy30-day postoperative period
Health-related quality of lifePostoperative (at 30 days)

Trial Locations

Locations (1)

Fox Chase Cancer Center

🇺🇸

Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath